Loyal announced it has raised $100 million in Series C funding, bringing total investment in the company to more than $250 million since its founding in 2019. The round was led by age1, the next generation of Laura Deming’s Longevity Fund, with participation from Baillie Gifford and existing investors. “Our driving purpose at Loyal is to help dogs live longer, healthier lives,” says Loyal founder & CEO Celine Halioua in a statement. “We’re closer than ever to delivering a solution to the problem we set out to solve: an FDA-approved drug for canine lifespan extension. This capital will help our team see our lead program through the remaining FDA requirements and get to market.” Loyal’s lead candidate, LOY-002, is a daily prescription pill designed to extend healthy lifespan in senior dogs by targeting underlying metabolic drivers of aging. The company has completed the Reasonable Expectation of Effectiveness and Target Animal Safety technical sections required for FDA Expanded Conditional Approval. The final major requirement is in progress, with submission reportedly planned later this year. The company also reported completing enrollment in its pivotal STAY study, which is following 1,300 dogs across 70 veterinary clinics nationwide. According to Loyal, it is the largest clinical trial conducted in veterinary medicine. For more information, visit the Loyal website.
